This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Reports for Netflix, Medtronic & Stryker
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Medtronic (MDT), and Stryker (SYK).
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect strength in the Global Healthcare and Life Sciences segment.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Why the Earnings Surprise Streak Could Continue for Stryker (SYK)
by Zacks Equity Research
Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako and broad product portfolio. However, pricing pressure raises a concern.
What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
Coronavirus Ups the Game for Robotic Surgery: 3 Stocks on Radar
by Sriparna Ghosal
Let's keep a watch on the potentially strong three MedTech stocks, namely SYK, ARAY and MDT with respect to robotic-assisted surgery that showed promises during the pandemic.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Stryker (SYK) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings reflect strong segmental performance.
Stryker (SYK) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 10.20% and -0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Colfax's (CFX) Unit Closes Buyout of Trilliant Surgical
by Zacks Equity Research
Colfax (CFX) arm DJO closes buyout of Trilliant Surgical, which will boost its product offerings and growth prospects in the foot and ankle surgery market.
5 Robotics Stocks to Watch Amid Rising Shift to Automation
by Zacks Equity Research
The robotics sector looks poised for a turnaround given the rapid shift to digitization and automation, making it wise to keep an eye on names like iRobot (IRBT), Ambarella (AMBA) and Stryker (SYK)
Stryker (SYK) Buys OrthoSensor to Grow in Sensor Technology
by Zacks Equity Research
Stryker's (SYK) acquisition of OrthoSensor will help surgeons with real-time data-driven solutions and improve patient outcomes.
The Zacks Analyst Blog Highlights: Trimble, Rockwell Automation, ReWalk Robotics, Fanuc and Stryker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Trimble, Rockwell Automation, ReWalk Robotics, Fanuc and Stryker
LabCorp's (LH) Covance Arm Stays Robust Amid Procedure Delay
by Zacks Equity Research
Apart from COVID-19 supports, LabCorp (LH) is making significant strides in other businesses.
Allscripts (MDRX) Completes Sale of CarePort Health Business
by Zacks Equity Research
Allscripts' (MDRX) agreement with WellSky empowers providers with efficient care transitions and better patient health outcomes.
Robots Will Rule 2021: 5 Stocks Poised to Benefit
by Sreoshi Bera
Robotics stocks are poised to grow in 2021, calling for investment in Trimble (TRMB), Rockwell Automation (ROK), ReWalk Robotics (RWLK), Fanuc Corp (FANUY) and Stryker (SYK).
Here's Why You Should Retain Stryker Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Colfax (CFX) Arm's LiteCure Buyout to Boost Product Portfolio
by Zacks Equity Research
Colfax's (CFX) acquisition of LiteCure will create strong growth opportunities for DJO in the physical therapy and rehabilitation market.
Colfax (CFX) to Gain From Products & Buyouts Amid Pandemic Woes
by Zacks Equity Research
Colfax's (CFX) product launches, exposure in multiple markets and gains from buyouts to prove beneficial. However, the pandemic-led challenges and lower selling days remain concerning for Q4.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Colfax (CFX) Arm DJO Acquires Stryker's Extremity Products
by Zacks Equity Research
Colfax (CFX) arm DJO closes buyout of products/system related to ankle replacement and finger arthroplasty from Stryker, which will boost its product offerings in the reconstructive products space.
3 Stocks to Capitalize on Promising Medical Products Industry
by Trina Mukherjee
Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.